The global market for Diabetic Gastroparesis Treatment was valued at US$2.3 Billion in 2024 and is projected to reach US$2.7 Billion by 2030, growing at a CAGR of 2.6% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Diabetic Gastroparesis Treatment market.
One of the most significant trends is the transition from symptomatic treatment to targeted motility-modulating agents. Historically managed with dietary modifications, antiemetics, and off-label use of prokinetics, the market is now witnessing a resurgence in pharmaceutical R&D focused on selective serotonin receptor agonists, ghrelin receptor agonists, and CGRP antagonists. These innovations aim to address the underlying pathophysiology of impaired gastric motility rather than merely suppress symptoms.
Other drugs in clinical trials include velusetrag (5-HT4 agonist) and camicinal, both designed to selectively stimulate gastrointestinal motility without cardiovascular or neurological risks. Additionally, botulinum toxin injections into the pyloric sphincter and gastric electrical stimulation are being explored as interventional options for refractory cases. These advancements are shifting the focus toward personalized, mechanism-based therapies, particularly for patients with severe symptoms and delayed gastric emptying confirmed by gastric scintigraphy.
Endocrinologists, gastroenterologists, and diabetologists are key prescribers, with treatment decisions often requiring multidisciplinary coordination. Academic medical centers and tertiary referral hospitals play a crucial role in diagnosing and managing severe cases, while pharmaceutical companies are working closely with these institutions to conduct clinical trials and expand therapeutic indications. Moreover, diabetic patient advocacy groups and telemedicine platforms are contributing to earlier recognition of symptoms, thereby improving treatment access and adherence.
Pharmaceutical innovation is a key growth driver, with new classes of prokinetics and symptom-targeted therapies entering late-stage clinical development. These agents offer improved tolerability and efficacy, positioning them as safer long-term solutions in a field previously dominated by off-label and side-effect-prone treatments. Additionally, improvements in health insurance coverage for diagnostic tests and specialty consultations are aiding market penetration in developed countries.
The convergence of digital health tools - including remote symptom tracking apps, wearable glycemic monitors, and AI-assisted dietary management platforms - is also fostering more individualized treatment plans. These technological integrations, along with targeted education campaigns and expanding clinical trials, are reshaping how diabetic gastroparesis is understood, managed, and monetized across global healthcare systems.
Segments: Product Type (Drugs, Surgical Treatment Products); Disease Indication (Compensated Gastroparesis, Gastric Failure); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Diabetic Gastroparesis Treatment Market - Key Trends & Drivers Summarized
Is Therapeutic Innovation Catching Up With an Underdiagnosed Condition?
Diabetic gastroparesis - a chronic gastric motility disorder caused by long-term diabetes - remains one of the most underdiagnosed and difficult-to-treat complications of diabetes. It primarily affects individuals with Type 1 and long-standing Type 2 diabetes, leading to delayed gastric emptying, nausea, vomiting, bloating, and impaired glycemic control. The global diabetic gastroparesis treatment market is now undergoing a transformation, driven by growing disease awareness, diagnostic improvements, and the introduction of novel prokinetic therapies.One of the most significant trends is the transition from symptomatic treatment to targeted motility-modulating agents. Historically managed with dietary modifications, antiemetics, and off-label use of prokinetics, the market is now witnessing a resurgence in pharmaceutical R&D focused on selective serotonin receptor agonists, ghrelin receptor agonists, and CGRP antagonists. These innovations aim to address the underlying pathophysiology of impaired gastric motility rather than merely suppress symptoms.
How Is R&D Reshaping the Therapeutic Landscape for Gastroparesis?
Traditional treatment approaches have long relied on metoclopramide, domperidone, erythromycin, and ondansetron. However, their long-term use is limited by adverse effects such as extrapyramidal symptoms, QT prolongation, and tachyphylaxis. In response, pharmaceutical companies are developing more targeted, better-tolerated prokinetic agents. Promising candidates include relamorelin, a ghrelin receptor agonist that enhances gastric emptying and shows potential in reducing symptom severity with fewer CNS side effects.Other drugs in clinical trials include velusetrag (5-HT4 agonist) and camicinal, both designed to selectively stimulate gastrointestinal motility without cardiovascular or neurological risks. Additionally, botulinum toxin injections into the pyloric sphincter and gastric electrical stimulation are being explored as interventional options for refractory cases. These advancements are shifting the focus toward personalized, mechanism-based therapies, particularly for patients with severe symptoms and delayed gastric emptying confirmed by gastric scintigraphy.
Where Is Demand Emerging and Who Are the Primary Stakeholders?
The diabetic gastroparesis treatment market is concentrated in regions with high diabetes prevalence - particularly in North America, Western Europe, China, and India. The U.S. leads the market in terms of both diagnosis rates and treatment adoption due to greater access to motility testing and specialized gastroenterology services. However, underdiagnosis remains a major hurdle globally, as symptoms often overlap with other gastrointestinal conditions and lack standardized evaluation protocols.Endocrinologists, gastroenterologists, and diabetologists are key prescribers, with treatment decisions often requiring multidisciplinary coordination. Academic medical centers and tertiary referral hospitals play a crucial role in diagnosing and managing severe cases, while pharmaceutical companies are working closely with these institutions to conduct clinical trials and expand therapeutic indications. Moreover, diabetic patient advocacy groups and telemedicine platforms are contributing to earlier recognition of symptoms, thereby improving treatment access and adherence.
What’s Driving Growth in the Diabetic Gastroparesis Treatment Market?
The growth in the diabetic gastroparesis treatment market is driven by several factors tied to diabetes incidence, unmet clinical need, and emerging pharmacological solutions. The global rise in diabetes - particularly in younger adults and the aging population - has significantly expanded the potential patient pool for gastroparesis, especially in poorly managed or insulin-dependent cases. Increasing awareness and availability of gastric motility diagnostics are also improving detection and differentiation from other GI disorders.Pharmaceutical innovation is a key growth driver, with new classes of prokinetics and symptom-targeted therapies entering late-stage clinical development. These agents offer improved tolerability and efficacy, positioning them as safer long-term solutions in a field previously dominated by off-label and side-effect-prone treatments. Additionally, improvements in health insurance coverage for diagnostic tests and specialty consultations are aiding market penetration in developed countries.
The convergence of digital health tools - including remote symptom tracking apps, wearable glycemic monitors, and AI-assisted dietary management platforms - is also fostering more individualized treatment plans. These technological integrations, along with targeted education campaigns and expanding clinical trials, are reshaping how diabetic gastroparesis is understood, managed, and monetized across global healthcare systems.
Report Scope
The report analyzes the Diabetic Gastroparesis Treatment market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Product Type (Drugs, Surgical Treatment Products); Disease Indication (Compensated Gastroparesis, Gastric Failure); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Drugs segment, which is expected to reach US$1.7 Billion by 2030 with a CAGR of a 3.3%. The Surgical Treatment Products segment is also set to grow at 1.6% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $622.2 Million in 2024, and China, forecasted to grow at an impressive 5.2% CAGR to reach $519.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Diabetic Gastroparesis Treatment Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Diabetic Gastroparesis Treatment Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Diabetic Gastroparesis Treatment Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Abbott Laboratories, AbbVie Inc., Alfa Wassermann S.p.A., AstraZeneca plc, Bausch Health Companies Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Diabetic Gastroparesis Treatment market report include:
- Abbott Laboratories
- AbbVie Inc.
- Alfa Wassermann S.p.A.
- AstraZeneca plc
- Bausch Health Companies Inc.
- Bayer AG
- Boston Scientific Corporation
- C. R. Bard, Inc. (BD)
- Cardinal Health, Inc.
- Cipla Limited
- Evoke Pharma, Inc.
- GlaxoSmithKline plc
- Janssen Global Services, LLC
- Medtronic plc
- Neurogastrx, Inc.
- Pfizer Inc.
- Rhythm Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Vanda Pharmaceuticals, Inc.
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Alfa Wassermann S.p.A.
- AstraZeneca plc
- Bausch Health Companies Inc.
- Bayer AG
- Boston Scientific Corporation
- C. R. Bard, Inc. (BD)
- Cardinal Health, Inc.
- Cipla Limited
- Evoke Pharma, Inc.
- GlaxoSmithKline plc
- Janssen Global Services, LLC
- Medtronic plc
- Neurogastrx, Inc.
- Pfizer Inc.
- Rhythm Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
- Vanda Pharmaceuticals, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 368 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.3 Billion |
| Forecasted Market Value ( USD | $ 2.7 Billion |
| Compound Annual Growth Rate | 2.6% |
| Regions Covered | Global |
